Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11529405 MDR

Patent 11529405 was granted and assigned to Janssen Pharmaceuticals on December, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Janssen Pharmaceuticals

Current Assignee

Janssen Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11529405

Date of Patent

December 20, 2022

Patent Application Number

17167595

Date Filed

February 4, 2021

Patent Citations

‌

US Patent 10577592 Compositions and methods for protein glycosylation

‌

US Patent 10583185 Methods and compositions for immune protection against extra-intestinal pathogenic

‌

US Patent 10940191 MDR

‌

US Patent 10940192 Polysaccharide and uses thereof

‌

US Patent 11033633 ExPEC glycoconjugate vaccine formulations

‌

US Patent 11015177 Compositions and methods for protein glycosylation

‌

US Patent 10150952 Compositions and methods for protein glycosylation

‌

US Patent 10159751 ExPEC glycoconjugate vaccine formulations

...

Patent Primary Examiner

‌

Brian Gangle

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR)

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11529405 MDR

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API